These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22679810)

  • 1. [Efficiency of endovascular re-interventions for evolving restenosis of different types of stents].
    Gerasimov AM; Cherkavskaia OV; Rudenko BA; Ageev FT; Savchenko AP
    Vestn Rentgenol Radiol; 2012; (1):21-7. PubMed ID: 22679810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of implantation of drug-eluting stents in extensive lesion of the coronary bed according to angiographic and intravascular ultrasound findings].
    Cherkavskaia OV; Savchenko AP; Rudenko BA; Merkulov EV
    Vestn Rentgenol Radiol; 2012; (2):14-9. PubMed ID: 22730754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study.
    Rittger H; Brachmann J; Sinha AM; Waliszewski M; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Breithardt OA; Schmidt M; Zimmermann S; Lonke S; von Cranach M; Nguyen TV; Daniel WG; Wöhrle J
    J Am Coll Cardiol; 2012 Apr; 59(15):1377-82. PubMed ID: 22386286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
    Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
    J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.
    Song HG; Park DW; Kim YH; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Han S; Seong IW; Lee NH; Lee BK; Lee K; Lee SW; Nah DY; Park SJ
    J Am Coll Cardiol; 2012 Mar; 59(12):1093-100. PubMed ID: 22421303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical results of the use of new bioengineering technologies (endothelial precursor cell-capturing stents) in the treatment of coronary heart disease].
    Cherkavskaia OV; Rudenko BA; Kochetov AG; Savchenko AP; Gerasimov AM
    Vestn Rentgenol Radiol; 2012; (1):9-16. PubMed ID: 22679808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era.
    Lee MS; Pessegueiro A; Zimmer R; Jurewitz D; Tobis J
    J Invasive Cardiol; 2008 Aug; 20(8):401-3. PubMed ID: 18688064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-eluting balloon in the treatment of a recurrent in-stent restenosis of drug-eluting stent].
    Merkely B; Jambrik Z
    Orv Hetil; 2010 Sep; 151(37):1509-14. PubMed ID: 20807698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry.
    Abe M; Kimura T; Morimoto T; Taniguchi T; Yamanaka F; Nakao K; Yagi N; Kokubu N; Kasahara Y; Kataoka Y; Otsuka Y; Kawamura A; Miyazaki S; Nakao K; Horiuchi K; Ito A; Hoshizaki H; Kawaguchi R; Setoguchi M; Inada T; Kishi K; Sakamoto H; Morioka N; Imai M; Shiomi H; Nonogi H; Mitsudo K;
    Circulation; 2010 Jul; 122(1):42-51. PubMed ID: 20566954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
    Hermiller JB; Nikolsky E; Lansky AJ; Applegate RJ; Sanz M; Yaqub M; Sood P; Cao S; Sudhir K; Stone GW
    EuroIntervention; 2011 Jul; 7(3):307-13. PubMed ID: 21729832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-stent restenosis.
    Kim MS; Dean LS
    Cardiovasc Ther; 2011 Jun; 29(3):190-8. PubMed ID: 20406239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In-stent-stenosis of a bare-metal stent 11 years after its implantation].
    Skarlos AC; Zahn R; Zeymer U
    Dtsch Med Wochenschr; 2010 May; 135(21):1067-70. PubMed ID: 20486056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M
    Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
    Ramsdale DR; Rao A; Asghar O; Ramsdale KA; McKay E
    J Invasive Cardiol; 2008 Oct; 20(10):493-500. PubMed ID: 18829991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
    Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
    Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden.
    James SK; Stenestrand U; Lindbäck J; Carlsson J; Scherstén F; Nilsson T; Wallentin L; Lagerqvist B;
    N Engl J Med; 2009 May; 360(19):1933-45. PubMed ID: 19420363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.